产品编号：L175502
产品规格：
产品价格：面议
| 标准品编号: | L175502 |
| 名称: | Lapaquistat-d9 Acetate |
| 别名: | 1-[2-[(3R,5S)-1-[3-(Acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-piperidineacetic Acid-d9; (3R-trans)-1-[[1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-piperidineacetic Acid-d9; TAK 475-d9; |
| CAS号: | 1292841-28-1 |
| 参考CAS号: | 189060-13-7-unlabelled |
| 分子式: | C₃₃H₃₂D₉ClN₂O₉ |
| 分子量: | 654.2 |
| 种类: | Standards; Isotopic Labeled Analogues; Enzyme Activators and Inhibitors; Pharmaceutical/API Drug Impurities/Metabolites; |
| 应用: | A novel labelled squalene synthase inhibitor. Lapaquistat acetate decreased plasma cholesterol and triglyceride levels, by lowering lipoproteins containing apoB100. Treatment with Lapaquistat acetate increased collagen concentration and transformed coronary plaques into fibromuscular plaques. Lapaquistat acetate also suppressed the expression of matrix metalloproteinase-1 and plasminogen activator inhibitor-1 in the plaque and increased peripheral coenzyme Q10 levels. Antiarteriosclerotics. |
| 参考文献 | |
